SNI-2011 TO TREAT PATIENTS WITH SJOGREN'S SYNDROME

SNI-2011 治疗干燥综合征患者

• 批准号: 6121144
• 负责人: ALAN W FRIEDMAN
• 金额: $ 1.51万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6121144
• 关键词: Sjogren's syndrome; cholinergic agents; clinical research; human subject; human therapy evaluation; immunopathology chemotherapy

Sjogren's syndrome is an immunological disorder characterized by dry eyes and dry mouth, which includes diminished or absent secretion of glandular tissue. SNI-2011, a quinuclidine derivative of acetylcholine, is a muscarinic agonist associated with improved glandular ability to increase salivation and lacrima-tion. This study will compare the efficacy of two doses of SNI-2011 (15 mg and 30 mg tid) with placebo on the patients' subjective global evaluation of dryness (mouth, eyes, and overall).

干燥综合征是一种免疫性疾病，其特征在于眼干和口干，其包括腺体组织分泌减少或缺乏。 SNI-2011是乙酰胆碱的奎宁环衍生物，是一种毒蕈碱激动剂，可改善腺体分泌唾液和流泪的能力。 本研究将比较两种剂量的SNI-2011（15 mg和30 mg tid）与安慰剂对患者干燥（口、眼和总体）的主观总体评价的疗效。